Clinical Differences in Hospitalized Adult Influenza Patients between the A (H1N1) pdm09 and the A (H3N2) Seasons in Japan

Nozomi Oikawa, M. Seki
{"title":"Clinical Differences in Hospitalized Adult Influenza Patients between the A (H1N1) pdm09 and the A (H3N2) Seasons in Japan","authors":"Nozomi Oikawa, M. Seki","doi":"10.4172/2332-0877.1000353","DOIUrl":null,"url":null,"abstract":"To determine the differences in the clinical features of hospitalized elderly patients with influenza between the A (H1N1) pdm09 and the A (H3N2)-dominant seasons, 12 adult patients (mean age, 76.5 years) with influenza who were hospitalized during the 2015-2016 A (H1N1) pdm09-dominant season were compared with 26 adult patients (mean age, 82.5 years) with influenza who were hospitalized during the 2016-2017 A (H3N2)-dominant season. Compared with the A (H3N2)-dominant 2016-2017 season, the A (H1N1) pdm09-dominant 2015-2016 season had fewer non-survivors, but had significantly fewer patients who required oxygenation/respirator support and intravenous anti-influenza agents, such as peramivir. Among the severe patients who received oxygenation/respirator support, the outcomes were better in the A (H3N2)-dominant 2016-2017 season than in the A (H1N1) pdm09-dominant 2015-2016 season. The pneumonia types and detected bacteria did not differ between the two seasons, but the use of sulbactam/ampicillin was more frequent in the A (H1N1) pdm09-dominant 2015-2016 season than in the A (H3N2)-dominant 2016-2017 season. These data suggest that peramivir treatment and oxygenation/respirator support, but not sulbactam/ampicillin administration, may improve the outcome of severe elderly patients hospitalized for influenza, especially the A (H3N2) type.","PeriodicalId":73792,"journal":{"name":"Journal of infectious disease and therapy","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4172/2332-0877.1000353","citationCount":"7","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of infectious disease and therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4172/2332-0877.1000353","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 7

Abstract

To determine the differences in the clinical features of hospitalized elderly patients with influenza between the A (H1N1) pdm09 and the A (H3N2)-dominant seasons, 12 adult patients (mean age, 76.5 years) with influenza who were hospitalized during the 2015-2016 A (H1N1) pdm09-dominant season were compared with 26 adult patients (mean age, 82.5 years) with influenza who were hospitalized during the 2016-2017 A (H3N2)-dominant season. Compared with the A (H3N2)-dominant 2016-2017 season, the A (H1N1) pdm09-dominant 2015-2016 season had fewer non-survivors, but had significantly fewer patients who required oxygenation/respirator support and intravenous anti-influenza agents, such as peramivir. Among the severe patients who received oxygenation/respirator support, the outcomes were better in the A (H3N2)-dominant 2016-2017 season than in the A (H1N1) pdm09-dominant 2015-2016 season. The pneumonia types and detected bacteria did not differ between the two seasons, but the use of sulbactam/ampicillin was more frequent in the A (H1N1) pdm09-dominant 2015-2016 season than in the A (H3N2)-dominant 2016-2017 season. These data suggest that peramivir treatment and oxygenation/respirator support, but not sulbactam/ampicillin administration, may improve the outcome of severe elderly patients hospitalized for influenza, especially the A (H3N2) type.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
日本A (H1N1) pdm09和A (H3N2)季节住院成人流感患者的临床差异
为确定甲流pdm09和甲流H3N2优势季节住院老年流感患者临床特征的差异,将2015-2016年甲流pdm09优势季节住院的12例成人流感患者(平均年龄76.5岁)与2016-2017年甲流H3N2优势季节住院的26例成人流感患者(平均年龄82.5岁)进行比较。与2016-2017年A (H3N2)为主的流感季相比,2015-2016年A (H1N1) pdm09为主的流感季的非幸存者人数较少,但需要氧配合/呼吸机支持和静脉注射抗流感药物(如帕拉米韦)的患者人数明显减少。在接受氧合/呼吸机支持的重症患者中,2016-2017年以A (H3N2)为主季节的预后优于2015-2016年以A (H1N1) pdm09为主季节的预后。肺炎类型和检测到的细菌在两个季节之间没有差异,但在2015-2016年以A (H1N1) pdm09为主的季节使用舒巴坦/氨苄西林的频率高于2016-2017年以A (H3N2)为主的季节。这些数据表明,帕拉米韦治疗和氧合/呼吸机支持,而不是舒巴坦/氨苄西林治疗,可能改善因流感住院的严重老年患者的预后,特别是A (H3N2)型。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Mycobacterial Nucleic Acids Modulate Host Innate Immune Responses. Streptococcus Pharyngitis with Anaerobes Infection Misdiagnosed as Mycobacterium Tuberculosis Infection: A Case Report The Intervening Effect of Preventive Use of Antibacterials During the Perioperative Period in Orthopedic Department Outcome Comparison Between Tocilizumab Alone Vs Tocilizumab Followed by Intravenous Immunoglobulin (IVIG) Group in Critical COVID-19 Disease To What Extent do Social Determinants of Health Modulate Presentation, ITU Admission and Outcomes among Patients with SARS-COV-2 Infection? An Exploration of Household Overcrowding, Air Pollution, Housing Quality, Ethnicity, Comorbidities and Frailty.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1